Dr. Rotkis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
621 Memorial Dr
South Bend, IN 46601Phone+1 574-236-1888Fax+1 574-236-1887
Education & Training
Akron General Medical Center/NEOMEDResidency, Surgery, 1995 - 2000
The University of Toledo College of MedicineClass of 1995
Certifications & Licensure
IN State Medical License 2000 - 2025
OH State Medical License 1997 - 1998
American Board of Surgery Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Publications & Presentations
PubMed
- 31 citationsPertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).Peter D. Beitsch, Pat Whitworth, Paul L. Baron, Michael Rotkis, Angela Mislowsky
Annals of Surgical Oncology. 2017-04-26 - 59 citationsChemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted b...Pat Whitworth, Peter D. Beitsch, Angela Mislowsky, James Pellicane, Charles Nash
Annals of Surgical Oncology. 2017-03-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
